Computationally Designed VLP Vaccines
By utilizing computationally designed proteins that self-assemble into virus-like particles (VLPs), we are able to readily manufacture VLPs displaying complex antigens to target significant unmet medical needs.
RSV and Covid-19 Vaccines
Our vaccine candidates for respiratory syncytial virus (RSV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, have the potential to induce high neutralizing antibody titers for more effective protection.
Icosavax is dedicated to advancing vaccines against severe life-threatening respiratory diseases to protect our most at-risk populations.
In the News
Icosovax is turning its virus-like particle (VLP) technology to fight COVID-19. The news accompanies $16.5 million in new funding from the Bill and Melinda Gates Foundation and Open Philanthropy, and the publication of preclinical data in Cell.
Preclinical data published in Cell show the company’s COVID-19 vaccine candidate induces high neutralizing antibody titers after a single administration
BioSpace reporter Gail Dutton reports on Icosavax's computationally designed virus-like particle (VLP)